PRESS RELEASE AB SCIENCE ANNOUNCES A SLIGHT DELAY IN THE PUBLICATION OF ITS 2023 ANNUAL FINANCIAL REPORT THE COMPANY WILL PUBLISH ITS 2023 ANNUAL FINANCIAL REPORT NO LATER THAN 15 MAY 2024 Paris,...
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS GRANTED ELIGIBILITY FOR RECONSIDERATION REQUEST FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS Paris, 3 April, 2024,...
AB Science: New research shows that masitinib limits neuronal damage
AB Science provides a summary of the live webcast held on March 4, 2024
AB Science announces that firms have initiated coverage of the Company
AB Science will host webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
AB Science will host webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS ISSUED A NOTICE OF NON-COMPLIANCE-WITHDRAWAL (NON/w) FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AB SCIENCE INTENDS TO SUBMIT A REQUEST...
PRESS RELEASE AB SCIENCE ANNOUNCES AN UPDATE IN THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AT THE EUROPEAN MEDICINES AGENCY A DECISION FROM THE EUROPEAN...
PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2036 IN THE TREATMENT OF MASTOCYTOSIS THIS DECISION FURTHER STRENGTHENS MASITINIB™S INTELLECTUAL...